Pharmafile Logo

Durysta

- PMLiVE

Cellectis gets FDA nod for ‘off-the-shelf’ CAR-T trial

Investigational New Drug gets go-ahead for trials in patients with two haematological cancers

- PMLiVE

Keytruda filed for first- and second-line bladder cancer

Merck & Co hopes to gain advantage over Opdivo and Tecentriq with first-line setting

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

- PMLiVE

FDA approves Synergy’s constipation drug Trulance

Set to launch by March this year, analysts say the CIC therapy could see sales of $450m by 2020

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

Allergan logo

Allergan plans to file oral uterine fibroid drug in US by year-end

Analysts predict treatment will reach blockbuster sales as phase III trials meet objectives

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

Ashley Communications celebrates 20 years of medical communications

Looks forward with new business wins, including AbbVie and Merck & Co accounts

FDA: Cybersecurity is an ever-present risk for medical devices

US regulator issues new guidance for manufacturers

Bayer symbol

Bayer nets speedy US review for regorafenib in liver cancer

Priority review in HCC boosts hopes for rejuvenation of Stivarga to combat declining sales

Biogen Idec building

FDA approves Biogen’s Spinraza for spinal muscular atrophy

Analysts predict blockbuster sales as drug is priced at $750,000 for first year of treatment

- PMLiVE

Allergan buys regenerative medicine firm LifeCell for $2.9bn

Acquired company focuses on plastic surgery and hernia repair procedures

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links